Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHRH in Mild Cognitive Impairment
NCT02553603Phase 1Completed
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of tesamorelin in Mild Cognitive Impairment (MCI) (4 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoints: Cognitive Function measured by SLUMS at 10 weeks, Brain Perfusion measured by fMRI at 10 weeks and 1 more. Started Jul 2017; status: completed.
02
Drugs
tesamorelin
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02553603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553603.